(5-碘-吡啶-2-基)-肼 | 77992-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (5-碘-吡啶-2-基)-肼
• 英文名称: 2-hydrazinyl-5-iodopyridine
• 英文别名: 2-hydrazino-5-iodopyridine；(5-iodopyridin-2-yl)hydrazine
• CAS: 77992-46-2
• 化学式: C₅H₆IN₃
• 分子量: 235.027
• InChiKey: XFEWGDAERUEGIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (5-碘-吡啶-2-基)-肼 在 三氟化硼乙醚 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 8.5h， 生成 6-iodo-3,3-dimethoxy-2-(propan-2-ylidene)-2,3-dihydro[1,2,4,3]triazaborolo[4,5-a]pyridin-2-ium-3-uide
  参考文献：
  名称：

  Design and Synthesis of a New Class of Membrane-Permeable Triazaborolopyridinium Fluorescent Probes

  摘要：

  A new class of fluorescent triazaborolopyridinium compounds was synthesized from hydrazones of 2-hydrazinylpyridine (HPY) and evaluated as potential dyes for live-cell imaging applications. The HPY dyes are small, their absorption/emission properties are tunable through variation of pyridyl or hydrazone substituents, and they offer favorable photophysical characteristics featuring large Stokes shifts and general insensitivity to solvent or pH. The stability, neutral charge, cell membrane permeability, and favorable relative influences on the water solubility of HPY conjugates are complementary to existing fluorescent dyes and offer advantages for the development of receptor-targeted small-molecule probes. This potential was assessed through the development of a new class of cysteine-derived HPY-conjugate imaging agents for the kinesin spindle protein (KSP) that is expressed in the cytoplasm during mitosis and is a promising chemotherapeutic target. Conjugates possessing the neutral HPY or charged Alexa Fluor dyes that function as potent, selective allosteric inhibitors of the KSP motor were compared using biochemical and cell-based phenotypic assays and live-cell imaging. These results demonstrate the effectiveness of the HPY dye moiety as a component of probes for an intracellular protein target and highlight the importance of dye structure in determining the pathway of cell entry and the overall performance of small-molecule conjugates as imaging agents.

  DOI：

  10.1021/ja2005175
• 作为产物：
  描述：

  2-溴-5-碘吡啶 在 一水合肼 作用下， 以 异丙醇 为溶剂， 以90%的产率得到(5-碘-吡啶-2-基)-肼
  参考文献：
  名称：

  费歇尔环化法合成2,3-二取代的5-碘-1H-吡咯并[2,3-b]吡啶

  摘要：

  本文描述了一种简单方便的方法，该方法通过费希尔吲​​哚在多磷酸中环化，从容易获得的起始原料中制备一些未知的2,3-二取代的5-碘-1 H-吡咯并[2,3- b ]吡啶。本方法为5碘7氮杂吲哚支架的合成提供了另一种合成方法。所有合成的化合物均通过IR，MS，1 H和13 C NMR以及元素分析进行表征。

  DOI：

  10.1002/jhet.2865

文献信息

• Synthesis and Stability Evaluation of New HYNIC Derivatives as Ligands for Technetium-99m
  作者：Yoann Joyard、Laurent Bischoff、Vincent Levacher、Cyril Papamicael、Pierre Vera、Pierre Bohn

  DOI：10.2174/15701786113106660087

  日期：2014.2

  An efficient synthetic route to prepare two new HYNIC derivatives with a 2-nitroimidazole moiety designed for tumor hypoxia imaging is described. During the course of the synthesis, the optimization of N-alkylation reaction of 2- nitroimidazole with propargyl bromide is reported to favor the formation of the terminal alkyne versus allene. Thereafter, the two ligands were used with tricine/EDDA to complex 99mTc. However, decomposition of these ligands was observed and we suggest a reasonable explanation based on LC-MS analysis.

  描述了一种高效的合成路线，用于制备两种新型HYNIC衍生物，它们含有2-硝基咪唑结构，设计用于肿瘤乏氧显像。在合成过程中，报道了对2-硝基咪唑与丙炔基溴的N-烷基化反应的优化，这有利于形成末端炔烃而非丙二烯。随后，这两种配体与tricine/EDDA一起用于络合99mTc。然而，观察到了这些配体的分解现象，我们基于LC-MS分析给出了一个合理的解释。
• [EN] PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE PHENYLALANINE UTILISES COMME INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE DANS LE TRAITEMENT OU LA PREVENTION DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2004043940A1

  公开（公告）日：2004-05-27

  The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及苯丙氨酸衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防涉及二肽基肽酶-IV酶的疾病中具有用处，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及二肽基肽酶-IV酶的这类疾病中使用这些化合物和组合物。
• Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
  申请人：Xu Yong

  公开号：US09416132B2

  公开（公告）日：2016-08-16

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一的蛋白激酶（I）、（II）或（III）：或其立体异构体、前药、互变异构体或药用可接受盐，其中R、R1、R2和X如本文所定义。还公开了在治疗癌症、自身免疫、炎症和其他Pim激酶相关疾病中使用这些组合物和方法。
• [EN] HETEROCYCLIC PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE HÉTÉROCYCLIQUES
  申请人：TOLERO PHARMACEUTICALS INC

  公开号：WO2013013188A1

  公开（公告）日：2013-01-24

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一的蛋白激酶（I）、（II）或（III）：或其立体异构体、前药、互变异构体或药用可接受盐，其中R、R1、R2和X如本文所定义。还公开了在治疗癌症、自身免疫、炎症和其他Pim激酶相关疾病中使用这些蛋白激酶的组合物和方法。
• [EN] TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIDINE UTILISÉS COMME INHIBITEURS DE LA P38 MAP KINASE
  申请人：PULMAGEN THERAPEUTICS INFLAMMA

  公开号：WO2010094956A1

  公开（公告）日：2010-08-26

  Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract wherein; R1 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R3 and R4 are independently H or C1-C6 alkyl, or R3 and R4 taken together with the nitrogen to which they are attached form a 6- membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is -O- or -S(O)P- wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C3-C6 divale nt cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R2NHC(=O)W-; W is a bond, -NH- or -C(RA)(RB), wherein RA and RB are independently H, methyl, ethyl, amino, hydroxyl or halo; and R2 is a radical as defined in the claims.

  化合物的结构式（I）是p38 MAP激酶的抑制剂，在治疗呼吸道疾病等疾病中作为抗炎药物有用；其中，R1是C1-C6烷基，C3-C6环烷基，苯基（可选择性取代），5-或6-成员单环杂芳基（可选择性取代），或者是结构式（II）中的基团，其中n为1或2，R3和R4独立地是H或C1-C6烷基，或者R3和R4与它们连接的氮一起形成一个6-成员杂环环，可选择性地含有进一步从N和O中选择的杂原子；Y是-O-或-S(O)P-，其中p为0、1或2；A是一个可选择性取代的二价芳基基团，或者是一个单环或双环杂芳基基团，或者是一个具有5或6个环原子的C3-C6二价环烷基基团，或者是一个哌啶基团，其中环氮与R2NHC(=O)W-连接；W是一个键，-NH-或-C(RA)(RB)，其中RA和RB独立地是H、甲基、乙基、氨基、羟基或卤素；而R2是如权利要求中定义的基团。